Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?
- Conditions
- Metastatic prostate cancerTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2022-003788-13-FI
- Lead Sponsor
- Heikki Minn
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Male
- Target Recruitment
- 40
Men with histologically confirmed prostate cancer. Age 50-85 years.
WHO performance score 0-2.
At least one distant metastasis detected on CT, MRI, bone scintigraphy (BS) or single-photon emission computed tomography (SPECT) imaging.
All previous treatment lines are allowed.
Patient signs informed consent form after receiving written information.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30
Patient is not able to understand the purpose of the study.
Medical conditions prohibiting whole-body PET/CT imaging.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.